Table of Contents

1. Executive Summary

2. Seasonal Influenza Vaccine Market in Top Seven Countries – Market Overview

2.1 Seasonal Influenza Vaccine Market

2.2 Number of Persons Vaccinated with Influenza Vaccine

2.3 Seasonal Influenza Vaccine Market Share

2.4 Persons Being Vaccinated with Influenza Vaccine Share

3. Seasonal Influenza Vaccine Market Drivers and Barriers

3.1 Market Drivers

3.2 Market Barriers

4. Seasonal Influenza Vaccine Market in Top Seven Countries – Geographical Landscape

4.1 United States

4.1.1 Seasonal Influenza Vaccine Market

4.1.2 Total – Number of Persons Vaccinated with Seasonal Influenza Vaccine

4.1.2.1 Number of Children Vaccinated

4.1.2.2 Number of Adults Vaccinated

4.2 Germany

4.2.1 Seasonal Influenza Vaccine Market

4.2.2 Total – Number of Persons Vaccinated with Seasonal Influenza Vaccine

4.2.2.1 Number of 60+ Years of Age Persons Vaccinated

4.2.2.2 Number of Pregnant Women Vaccinated

4.2.2.3 Number of Chronic Medical Condition Persons Vaccinated

4.2.2.4 Number of Healthcare Workers Vaccinated

4.3 France

4.3.1 Seasonal Influenza Vaccine Market

4.3.2 Total – Number of Persons Vaccinated with Seasonal Influenza Vaccine

4.3.2.1 Number of 65+ Years of Age Persons Vaccinated

4.3.2.2 Number of Pregnant Women Vaccinated

4.3.2.3 Number of Chronic Medical Condition Persons Vaccinated

4.3.2.4 Number of Healthcare Workers Vaccinated

4.4 Italy

4.4.1 Seasonal Influenza Vaccine Market

4.4.2 Total – Number of Persons Vaccinated with Seasonal Influenza Vaccine

4.4.2.1 Number of 65+ Years of Age Persons Vaccinated

4.4.2.2 Number of Pregnant Women Vaccinated

4.4.2.3 Number of Chronic Medical Condition Persons Vaccinated

4.4.2.4 Number of Healthcare Workers Vaccinated

4.5 United Kingdom

4.5.1 Seasonal Influenza Vaccine Market

4.5.2 Total – Number of Persons Vaccinated with Seasonal Influenza Vaccine

4.5.2.1 Number of Children Vaccinated

4.5.2.2 Number of 65+ Years of Age Persons Vaccinated

4.5.2.3 Number of Pregnant Women Vaccinated

4.5.2.4 Number of Chronic Medical Condition Persons Vaccinated

4.5.2.5 Number of Healthcare Workers Vaccinated

4.6 Spain

4.6.1 Seasonal Influenza Vaccine Market

4.6.2 Total – Number of Persons Vaccinated with Seasonal Influenza Vaccine

4.6.2.1 Number of 65+ Years of Age Persons Vaccinated

4.6.2.2 Number of Pregnant Women Vaccinated

4.6.2.3 Number of Chronic Medical Condition Persons Vaccinated

4.6.2.4 Number of Healthcare Workers Vaccinated

4.7 Japan

4.7.1 Seasonal Influenza Vaccine Market

4.7.2 Total – Number of Persons Vaccinated with Seasonal Influenza Vaccine

4.7.2.1 Number of Children Vaccinated

4.7.2.2 Number of 65+ Years of Age Persons Vaccinated

4.7.2.3 Number of Pregnant Women Vaccinated

4.7.2.4 Number of Chronic Medical Condition Persons Vaccinated

4.7.2.5 Number of Healthcare Workers Vaccinated

5. Seasonal Influenza Vaccine Production & Distribution in United States

5.1 Vaccine Choices Remain Available for Patients, Providers

5.2 Seasonal Influenza Vaccine Price Trends

5.2.1 Pediatric Seasonal Influenza Vaccine Price Trends

5.2.2 Adult Seasonal Influenza Vaccine Price Trends

5.3 Seasonal Influenza Vaccine Production, Supply, and Allocation

5.4 Seasonal Influenza Vaccine Distribution & Demand

5.5 Seasonal Influenza Vaccine Effectiveness

5.6 Managing Influenza with Diagnostic Resources

5.7 Distribution Method of Seasonal Influenza Vaccination

6. Seasonal Influenza Vaccine Market – Regulatory Landscape

6.1 Registration Process and Regulations for Vaccine in the US

6.2 Registration Process and Regulations for Vaccine in the EU

6.3 Registration Process and Regulations for Vaccine in Japan

7. Market Dynamics – Mergers, Acquisitions, Key Agreements & Collaborations

7.1 Merger & Acquisitions

7.2 Collaborations Deal

7.3 Licensing, Exclusive & Distribution Agreement Deal

7.3.1 Licensing Agreement

7.3.2 Exclusive Agreement

7.3.3 Distribution Agreement

8. Seasonal Influenza Vaccine – Pipeline Assessment

8.1 Promising Vaccine in Clinical Development

8.2 Promising Vaccine in Early–Stage Development

9. Seasonal Influenza Vaccine – Clinical Trials Assessment by Phase and Trial Status

9.1 Year 2016

9.2 Year 2015

9.3 Year 2014

9.4 Year 2013

10. Key Companies Analysis

10.1 Sanofi Pasteur

10.1.1 Business Overview

10.1.2 Sanofi Pasteur – Influenza Vaccine Outlook

10.1.2.1 Fluzone High–Dose Vaccine

10.1.2.2 Fluzone Quadrivalent Vaccine

10.1.2.3 Intradermal (ID) Trivalent Influenza Vaccine

10.1.2.4 Vaxigrip Vaccine

10.1.3 Seasonal Influenza Vaccine Sales Analysis

10.2 GlaxoSmithKline (GSK)

10.2.1 GlaxoSmithKline(GSK) – Influenza Vaccine Outlook

10.2.1.1 Fluarix Quadrivalent

10.2.1.2 Flulaval Quadrivalent

10.2.2 Seasonal Influenza Vaccine Sales Analysis & Forecast

10.3 AstraZeneca

10.3.1 Business Overview

10.3.2 AstraZeneca – Influenza Vaccine Outlook

10.3.2.1 Fluenz Tetra/FluMist Quadrivalent

10.3.3 Seasonal Influenza Vaccine Sales Analysis

10.4 Protein Sciences Corporation

10.4.1 Business Overview

10.4.2 Protein Sciences Corporation – Seasonal Influenza Vaccine Outlook

10.4.2.1 Flublok

10.5 Seqirus (CSL Limited)

10.5.1 Business Overview

10.5.2 Seqirus – Influenza Vaccine Outlook

10.5.2.1 Flucelvax Quadrivalent

10.5.2.2 Afluria Quadrivalent

10.5.2.3 Agrippal

10.5.2.4 Fluad

10.5.2.5 Fluvirin

10.5.2.6 Fluvax

List of Tables

Table 5–1: United States Seasonal Influenza Vaccine Available,2016 – 17

Table 5–2: United States – Pediatric Seasonal Influenza Vaccine Price, 2016 – 2017

Table 5–3: United States – Adult Seasonal Influenza Vaccine Price, 2016 – 2017

Table 5–4: United States – Flu Vaccine Production, Supply, and Allocation

Table 5–5: Total Percentage of Flu Vaccines Released by Week,2016 – 2017

Table 5–6: Total Percentage of Flu Vaccines Released by Week,2015 – 2016

Table 5–7: Total Percentage of Flu Vaccines Released by Week,2014 – 2015

Table 5–8: Adjusted Vaccine Effectiveness Estimates for Influenza Seasons, 2005 – 2016

Table 5–9: Managing Influenza with Diagnostic Resources

Table 5–10: Distribution of Seasonal Influenza Vaccination

Table 6–1: United States – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization

Table 6–2: European Union – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization

Table 6–3: Japan – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization

Table 7–1: Influenza Vaccine Market – Merger & Acquisitions (Million US$),2003 – 2015

Table 7–2: Influenza Vaccine Market – Collaborations Deal,2007 – 2016

Table 7–3: Influenza Vaccine Market – Licensing Agreement,2007 – 2016

Table 7–4: Influenza Vaccine Market – Exclusive Agreement,2009 – 2016

Table 7–5: Influenza Vaccine Market – Distribution Agreement,2005 – 2016

Table 8–1: BiondVax Pharmaceuticals Ltd. – Clinical Trials

List of Figures

Figure 2–1: Top Seven Countries – Seasonal Influenza Vaccine Market (Million US$),2010 – 2015

Figure 2–2: Top Seven Countries – Forecast for Seasonal Influenza Vaccine Market (Million US$),2016 – 2022

Figure 2–3: Top Seven Countries – Number of Persons Vaccinated with Influenza Vaccine(Million),2010 – 2015

Figure 2–4: Top Seven Countries – Forecast for Number of Persons Vaccinated with Influenza Vaccine(Million),2016 – 2022

Figure 2–5: Top Seven Countries – Seasonal Influenza Vaccine Market Share (Percent),2010 – 2015

Figure 2–6: Top Seven Countries – Forecast for Seasonal Influenza Vaccine Market Share (Percent),2016 – 2022

Figure 2–7: Top Seven Countries – Number of Persons Vaccinated with Influenza Vaccine Share(Percent),2010 – 2015

Figure 2–8: Top Seven Countries – Forecast for Number of Persons Vaccinated with Influenza Vaccine Share(Percent),2016 – 2022

Figure 4–1: United States – Seasonal Influenza Vaccine Market (Million US$),2010 – 2015

Figure 4–2: United States – Forecast for Seasonal Influenza Vaccine Market (Million US$),2016 – 2022

Figure 4–3: United States – Total Number of Persons Vaccinated(Thousand), 2010 – 2015

Figure 4–4: United States – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022

Figure 4–5: United States – Number of Children Vaccinated(Thousand),2010 – 2015

Figure 4–6: United States – Forecast for Number of Children Vaccinated(Thousand),2016 – 2022

Figure 4–7: United States – Number of Adults Vaccinated(Thousand),2010 – 2015

Figure 4–8: United States – Forecast for Number of Adults Vaccinated(Thousand),2016 – 2022

Figure 4–9: Germany – Seasonal Influenza Vaccine Market (Million US$),2010 – 2015

Figure 4–10: Germany – Forecast for Seasonal Influenza Vaccine Market (Million US$),2016 – 2022

Figure 4–11: Germany – Total Number of Persons Vaccinated(Thousand), 2010 – 2015

Figure 4–12: Germany – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022

Figure 4–13: Germany – Number of 60+ Years of Age Persons Vaccinated(Thousand),2010 – 2015

Figure 4–14: Germany – Forecast for Number of 60+ Years of Age Persons Vaccinated(Thousand),2016 – 2022

Figure 4–15: Germany – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015

Figure 4–16: Germany – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022

Figure 4–17: Germany – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015

Figure 4–18: Germany – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022

Figure 4–19: Germany – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015

Figure 4–20: Germany – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022

Figure 4–21: France – Seasonal Influenza Vaccine Market (Million US$),2010 – 2015

Figure 4–22: France – Forecast for Seasonal Influenza Vaccine Market (Million US$),2016 – 2022

Figure 4–23: France – Total Number of Persons Vaccinated(Thousand), 2010 – 2015

Figure 4–24: France – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022

Figure 4–25: France – Number of 65+ Years of Age Persons Vaccinated(Thousand),2010 – 2015

Figure 4–26: France – Forecast for Number of 60+ Years of Age Persons Vaccinated(Thousand),2016 – 2022

Figure 4–27: France – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015

Figure 4–28: France – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022

Figure 4–29: France – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015

Figure 4–30: France – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022

Figure 4–31: France – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015

Figure 4–32: France – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022

Figure 4–33: Italy – Seasonal Influenza Vaccine Market (Million US$),2010 – 2015

Figure 4–34: Italy – Forecast for Seasonal Influenza Vaccine Market (Million US$),2016 – 2022

Figure 4–35: Italy – Total Number of Persons Vaccinated(Thousand), 2010 – 2015

Figure 4–36: Italy – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022

Figure 4–37: Italy – Number of 65+ Years of Age Persons Vaccinated(Thousand),2010 – 2015

Figure 4–38: Italy – Forecast for Number of 65+ Years of Age Persons Vaccinated(Thousand),2016 – 2022

Figure 4–39: Italy – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015

Figure 4–40: Italy – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022

Figure 4–41: Italy – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015

Figure 4–42: Italy – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022

Figure 4–43: Italy – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015

Figure 4–44: Italy – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022

Figure 4–45: United Kingdom – Seasonal Influenza Vaccine Market (Million US$),2010 – 2015

Figure 4–46: United Kingdom – Forecast for Seasonal Influenza Vaccine Market (Million US$),2016 – 2022

Figure 4–47: United Kingdom – Total Number of Persons Vaccinated(Thousand), 2010 – 2015

Figure 4–48: United Kingdom – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022

Figure 4–49: United Kingdom – Vaccination Coverage Rate (%)

Figure 4–50: United Kingdom – Number of Children Vaccinated(Thousand),2010 – 2015

Figure 4–51: United Kingdom – Forecast for Number of Children Vaccinated(Thousand),2016 – 2022

Figure 4–52: United Kingdom – Number of 65+ Years of Age Persons Vaccinated(Thousand),2010 – 2015

Figure 4–53: United Kingdom – Forecast for Number of 65+ Years of Age Persons Vaccinated(Thousand),2016 – 2022

Figure 4–54: United Kingdom – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015

Figure 4–55: United Kingdom – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022

Figure 4–56: United Kingdom – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015

Figure 4–57: United Kingdom – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022

Figure 4–58: United Kingdom – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015

Figure 4–59: United Kingdom – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022

Figure 4–60: Spain – Seasonal Influenza Vaccine Market (Million US$),2010 – 2015

Figure 4–61: Spain – Forecast for Seasonal Influenza Vaccine Market (Million US$),2016 – 2022

Figure 4–62: Spain – Total Number of Persons Vaccinated(Thousand), 2010 – 2015

Figure 4–63: Spain – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022

Figure 4–64: Spain – Number of 65+ Years of Age Persons Vaccinated(Thousand),2010 – 2015

Figure 4–65: Spain – Forecast for Number of 65+ Years of Age Persons Vaccinated(Thousand),2016 – 2022

Figure 4–66: Spain – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015

Figure 4–67: Spain – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022

Figure 4–68: Spain – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015

Figure 4–69: Spain – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022

Figure 4–70: Spain – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015

Figure 4–71: Spain – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022

Figure 4–72: Japan – Seasonal Influenza Vaccine Market (Million US$),2010 – 2015

Figure 4–73: Japan – Forecast for Seasonal Influenza Vaccine Market (Million US$),2016 – 2022

Figure 4–74: Japan – Total Number of Persons Vaccinated(Thousand), 2010 – 2015

Figure 4–75: Japan – Forecast for Total Number of Persons Vaccinated(Thousand), 2016 – 2022

Figure 4–76: Japan – Number of Children Vaccinated(Thousand), 2010 – 2015

Figure 4–77: Japan – Forecast for Number of Children Vaccinated(Thousand), 2016 – 2022

Figure 4–78: Japan – Number of 65+ Years of Age Persons Vaccinated(Thousand),2010 – 2015

Figure 4–79: Japan – Forecast for Number of 65+ Years of Age Persons Vaccinated(Thousand),2016 – 2022

Figure 4–80: Japan – Number of Pregnant Women Vaccinated(Thousand),2010 – 2015

Figure 4–81: Japan – Forecast for Number of Pregnant Women Vaccinated(Thousand),2016 – 2022

Figure 4–82: Japan – Number of Chronic Medical Condition Persons Vaccinated(Thousand),2010 – 2015

Figure 4–83: Japan – Forecast for Number of Chronic Medical Condition Persons Vaccinated(Thousand),2016 – 2022

Figure 4–84: Japan – Number of Healthcare Workers Vaccinated(Thousand),2010 – 2015

Figure 4–85: Japan – Forecast for Number of Healthcare Workers Vaccinated(Thousand),2016 – 2022

Figure 5–1: United States – Seasonal Influenza Vaccine Doses Distributed, By Season(Million),2010 – 2016

Figure 10–1: Sanofi Pasteur – Seasonal Influenza Vaccine Net Sales (Million US$),2011 – 2015

Figure 10–2: Sanofi Pasteur – Forecast for Seasonal Influenza Vaccine Net Sales (Million US$),2016 – 2022

Figure 10–3: GSK – Influenza Vaccine Net Sales (Million US$),2011 – 2015

Figure 10–4: GSK – Forecast for Influenza Vaccine Net Sales (Million US$),2016 – 2022

Figure 10–5: AstraZeneca – Influenza Vaccine Net Sales (Million US$),2011 – 2015